secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0000950170-22-026929
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences targets FDA De Novo resubmission around fiscal year end; cash $3.1M
--------------------------------------------------------------------------------

- Patient enrollment for MyoVista pivotal study near completion; resubmission target around April 2023 fiscal year-end.
- Cash and cash equivalents $3.1M as of Oct 31, 2022; sufficient through FDA resubmission.
- No meaningful revenue in Q2 fiscal 2023 as development-stage company.
- Entered multi-year collaboration with Rutgers University for AI algorithm development.
- AMA issued new Category III CPT codes covering AI assistive ECG risk assessments for cardiac dysfunction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/0000950170-22-026929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/hscs-20221222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer